Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada

Table 3 Assumed HPV distributions for each model health state for the base case and sensitivity analyses

Health state	HPV genotype	Canadian data	References	Base case estimates †	North America data	Sensitivity analysis estimates‡	References
	16/18	24.9%	[45]	24.9%	25.6%	22.0%	[60]
CIN1	CP*	33.6%		33.6%	67.5%	57.0%
	6/11	4.8%		4.8%	7.6%	6.0%
	Other	6.9%		36.7%	17.8%	15.0%
	16/18	56.2%	[45]	56.2%	55.2%	50.0%	[60]
CIN2/3	CP*	32.9%		32.9%	49.6%	45.0%
	Other	2.5%		10.9%	5.6%	5.0%
	16/18	74.3%	[45]	74.3%	76.5%	85.0%	[60]
Cancer	CP*	18.3%		18.3%	13.6%	15.0%
	Other	2.2%		7.4%	1.0%	0.0%
Genital Warts	6/11		[61]	76.2%		76.2%	[61]

* CP: Cross-protection – oncogenic HPV types affected by the vaccine: HPV-31,-33,-35,-39,-45,-51,-52,-56,-58,-59.
† The proportion in the other HPV category was increased as required so that all cervical outcomes were associated with an HPV infection.
‡ The sum of proportions of all HPV infections were equal to more than 100% for CIN1 and CIN2/3 lesions due to multiple HPV infections. For modelling purposes, the values in each HPV category were proportionally reduced so that sum of all HPV types equals 100% .
CC – Cervical cancer.
CIN – Cervical Intraepithelial Neoplasia.
HPV – Human papillomavirus.

ISSN: 1471-2458